# 114 - biomolecules-11-01624 Publication Packet Repair Report

**Lifecycle status:** `PASS`  

**OVERRIDEN BY CONNOR FOWLER ON 2026-08-26T07:36:18Z**

**HUMAN REVIEW HAS YIELDED SUFFICIENT EVIDENCE TO PASS THIS PACKET**

**Audit date:** 2026-08-25  
**Packet:** `2 - 10 - Active Literature / 1 - Clinical Medicine & Pharmacy / 114 - biomolecules-11-01624`

## Source identity and integrity

- Primary source: `biomolecules-11-01624.pdf`
  - Drive file ID: `1rXuNs7pDgQ5IFMoOom7jhvj0LxPEsxnh`
  - Exact title: *The Effects of Vitamin D on Immune System and Inflammatory Diseases*
  - Authors: Tomoka Ao; Junichi Kikuta; Masaru Ishii
  - Journal: *Biomolecules*. 2021;11(11):1624
  - DOI: `10.3390/biom11111624`
  - PMID: `34827621`
  - PMCID: `PMC8615708`
  - SHA-256: `f20506a8a8e50f9027596b9f9838007c584ee1ff388e70dd0958fb5aa56b7c76`
  - Usability: **PASS**. The nine-page PDF opens, is text-extractable, and all pages were rendered and visually inspected.
- Supplements: **none present or identified for this packet**.
- Main-text visual inventory: Figure 1 and Figure 2; no main-text tables or algorithms/workflows.
- Substantive article content is on pages 1-6; bibliography is on pages 7-9.

## Verification boundary

- Project/source-derived findings: publication identity, article type, substantive claims, uncertainty, visual content, ATOM extraction, SEA QA, and lifecycle status.
- External identity verification was limited to confirming PMID/PMCID against the same title and DOI.
- No external clinical evidence was substituted for the supplied review.

## Protocol governance note

The configured governing SEA file is named `summary-evaluation-appraisal-protocol-v4-compact.md`, but its internal heading identifies it as `Integrated Compact v3`. The supplied governing file content and the packet-specific execution gates were followed; this labeling inconsistency did not change the validation or lifecycle result.

## Prior artifact audit

Identity matching used title, DOI, PMID/PMCID, source metadata, and content rather than filename similarity.

Before repair:

- Identity-matched SEA HTML existed in the Clinical Medicine & Pharmacy HTML output folder.
- Identity-matched reference task queue existed in the Clinical Medicine & Pharmacy Markdown output folder.
- No identity-matched ATOM JSON, authoritative ATOM validation JSON, coverage JSON, SEA QA JSON, or processing report was found in the Clinical Medicine & Pharmacy output folders.
- The packet folder itself contained only the primary PDF.

## ATOM repair and validation

ATOM artifacts were regenerated from the current source using one shared publication identity and the authoritative project contracts.

- ATOM JSON: `GitHub Sync / Literature Review / Outputs / Clin Med Pharm / JSON / biomolecules-11-01624-atoms.json`
  - Drive file ID: `1aNicMEd4RiOqg-sMl9fSGWxlf1bTAKPt`
- ATOM validation JSON: `GitHub Sync / Literature Review / Outputs / Clin Med Pharm / JSON / biomolecules-11-01624-validation.json`
  - Drive file ID: `1bxzHsenAtI0Ra57j2DKR0S5XAQxulzVs`
- Coverage JSON: `GitHub Sync / Literature Review / Outputs / Clin Med Pharm / JSON / biomolecules-11-01624-coverage.json`
  - Drive file ID: `1-HTMuMfGgsnu4Pr3LPOLdUOZf-mTiOK_`

Validation result:

- 51 independently reviewable `LiteratureAtom` objects.
- One shared publication UUID across the set; all atom IDs are unique.
- `literature.py` Pydantic structural validation: **0 errors**.
- `literature_atom.schema.json` JSON Schema validation: **0 errors**.
- `literature_atoms.py` atom-kind sufficiency validation: **0 errors, 0 warnings**.
- Blocking ATOM errors: **0**.
- All atoms have reliable source anchors; source excerpts were checked against the current PDF text after normalized line-break/dehyphenation handling.
- Assertion origin was preserved and secondary-study results were not represented as if this narrative review generated primary-study data.

Schema boundary:

- The current LiteratureAtom schema is oriented toward primary literature and has no dedicated secondary-reported-result kind. Review-level summaries of cited studies were therefore represented as `other` with `secondary_reported_result` tagging and provenance anchored to this review, rather than being misclassified as primary trial results.

Direct semantic spot-checks:

1. Primary conclusion — **PASS**: supplementation has been used for inflammatory diseases, but effectiveness remains unclear.
2. Numerical claim / source inconsistency — **PASS**: the review describes vitamin D3 1200 IU/day as producing a significantly lower influenza A rate while printing 18.6% for the vitamin D group and 10.8% for placebo; the contradiction is preserved rather than silently corrected.
3. Limitation/uncertainty — **PASS**: causal interpretation of low vitamin D in RA/MS is explicitly uncertain, including possible reduced sunlight exposure in more active disease.
4. Figure 1 — **PASS**: TLR activation, VDR/CYP27B1, 25D-to-1,25D conversion, antimicrobial peptides, and autophagy are represented.
5. Figure 2 — **PASS**: the EAE immune-cell pathway involving dendritic cells, Th1/Th2/Treg balance, and macrophage cytokines is represented.

## SEA audit and QA

The existing identity-matched SEA HTML was audited against the same current PDF and does not require regeneration.

- SEA HTML: `GitHub Sync / Literature Review / Outputs / Clin Med Pharm / HTML / biomolecules-11-01624-sea.html`
  - Drive file ID: `1klezo8G2y5SQm9y5WQaYcdVGQU-K6Q4G`
  - SHA-256: `5a85c68ce1f14076184449632d3ba8b6bce6775038df79c82e5be42524bdd993`
- SEA QA JSON: `GitHub Sync / Literature Review / Outputs / Clin Med Pharm / JSON / biomolecules-11-01624-sea-qa.json`
  - Drive file ID: `1Qdwuhgtul0zCN5u8ZPj6ENCGqY6jkO1Q`

SEA result:

- HTML parseability: **PASS**.
- Exact title, DOI, PMID, PMCID, review type, and provenance: **PASS**.
- Source structure/methodological characterization: **PASS**; the SEA correctly identifies the source as a non-systematic narrative review and does not overstate it as a systematic review or treatment trial.
- Main claims and quantitative findings: **PASS**.
- Limitations/uncertainty: **PASS**.
- Figure 1 and Figure 2: both structurally represented and semantically spot-checked.
- Main-text tables: none; correctly recorded.
- Supplements: none identified; correctly recorded.
- TOC anchors resolve; no TODOs/placeholders, internal chat/file citation syntax, external scripts/stylesheets, or remote images were found.
- The source's influenza numerical-direction inconsistency is explicitly preserved and flagged.

## ATOM-SEA reconciliation

ATOM and SEA were reconciled to the same source file/hash and publication identity.

- Review-level conclusion on supplementation uncertainty: consistent.
- Influenza numerical-direction inconsistency: consistently preserved.
- RA/MS causal uncertainty: consistent.
- Immune-cell mechanism claims: consistent.
- Figure 1 and Figure 2 interpretations: consistent.
- No consequential cross-artifact contradiction or source-integrity issue remains after repair.

## Reference-processing gate

Existing queue:

- `GitHub Sync / Literature Review / Outputs / Clin Med Pharm / MD / biomolecules-11-01624-reference-queue.md`
  - Drive file ID: `1l4rl48PDIEAli6DxZkV4uoZiZU36IQD9`
  - Total references: **64**
  - Completed/checked entries: **0**
  - Unresolved/unchecked entries: **64**

The queue explicitly states that its bibliography entries are independent follow-up tasks. Its existence is therefore not evidence that reference processing is complete.

**Reference-processing gate: FAIL / incomplete.**

## Lifecycle action

- Assigned status: `PARTIAL - REPAIR REQUIRED`.
- The packet remains in `2 - 10 - Active Literature / 1 - Clinical Medicine & Pharmacy`.
- The packet was **not** moved to `90 - Processed` because reference processing is not demonstrably complete.
- A `BLOCKED - NEEDS RESOLUTION` classification is not warranted: the primary source is complete and usable, and ATOM/SEA now pass their validation/QA gates.

## Exact remaining task

Reconcile all 64 entries in `biomolecules-11-01624-reference-queue.md` against the live TBR / Active / Processed / Citation Bank lifecycle. For each citation, record a defensible existing/completed/routed/acquired/resolved disposition and perform any required routing or acquisition work. Only after all 64 references have defensible completion evidence should the packet completion gate be rerun. ATOM and SEA do not currently require further repair.
